Organon & Co’s recent filing unveils that its Director COX CARRIE SMITH acquired Company’s shares for reported $0.1 million on May 14 ’25. In the deal valued at $8.07 per share,12,469 shares were bought. As a result of this transaction, COX CARRIE SMITH now holds 12,469 shares worth roughly $0.11 million.
Then, Falcione Aaron bought 5,500 shares, generating $48,235 in total proceeds. Upon buying the shares at $8.77, the Chief Human Resources Officer now owns 62,974 shares.
Before that, Weaver Kirke bought 8,045 shares. Organon & Co shares valued at $74,054 were divested by the Gen. Counsel & Corp. Secy. at a price of $9.21 per share. As a result of the transaction, Weaver Kirke now holds 52,489 shares, worth roughly $0.47 million.
Evercore ISI downgraded its Organon & Co [OGN] rating to an In-line from a an Outperform in a research note published recently. A number of analysts have revised their coverage, including JP Morgan’s analysts, who decreased its forecast for the stock in early September from “a Neutral” to “an Underweight”. Goldman also remained covering OGN and has decreased its forecast on November 03, 2023 with a “Neutral” recommendation from previously “Buy” rating. Barclays started covering the stock on September 21, 2023. It rated OGN as “an Overweight”.
Price Performance Review of OGN
On Monday, Organon & Co [NYSE:OGN] saw its stock fall -0.44% to $9.00. Over the last five days, the stock has gained 3.33%. Organon & Co shares have fallen nearly -39.68% since the year began. Nevertheless, the stocks have fallen -58.43% over the past one year.
How much short interest is there in Organon & Co?
A steep rise in short interest was recorded in Organon & Co stocks on 2025-04-30, growing by 4.57 million shares to a total of 19.7 million shares. Yahoo Finance data shows the prior-month short interest on 2025-03-31 was 15.13 million shares. There was a rise of 23.18%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on March 16, 2023 when Raymond James began covering the stock and recommended ‘”an Outperform”‘ rating along with a $33 price target.
